Assessing potential therapeutics for fibroblast manipulation
Research type
Research Study
Full title
Use of blood isolates for assessing potential therapeutics for fibroblast manipulation
IRAS ID
306589
Contact name
Timothy Johnson
Contact email
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
The study aims to assess the effectiveness of various experimental medicines developed by Mestag Therapeutics. These are designed to modify cell behaviour and bring benefit in immune disorders and cancers where patient treatment options are limited. Immune cells isolated from blood samples will be used as a model to measure the immune response to Mestag's novel therapeutics, and as a base to differentiate into multiple cell types.
REC name
London - Queen Square Research Ethics Committee
REC reference
22/PR/0275
Date of REC Opinion
31 May 2022
REC opinion
Favourable Opinion